Skip to main content
Current Neuropharmacology logoLink to Current Neuropharmacology
. 2014 Sep;12(5):399–412. doi: 10.2174/1570159X12666140424233036

Combination of Therapeutic Hypothermia and Other Neuroprotective Strategies after An Ischemic Cerebral Insult#

Joline Goossens 1,*, Saïd Hachimi-Idrissi 1
PMCID: PMC4243031  PMID: 25426009

Abstract

Abrupt deprivation of substrates to neuronal tissue triggers a number of pathological events (the “ischemic cascade”) that lead to cell death. As this is a process of delayed neuronal cell death and not an instantaneous event, several pharmacological and non-pharmacological strategies have been developed to attenuate or block this cascade. The most promising neuroprotectant so far is therapeutic hypothermia and its beneficial effects have inspired researchers to further improve its protective benefit by combining it with other neuroprotective agents. This review provides an overview of all neuroprotective strategies that have been combined with therapeutic hypothermia in rodent models of focal cerebral ischemia. A distinction is made between drugs interrupting only one event of the ischemic cascade from those mitigating different pathways and having multimodal effects. Also the combination of therapeutic hypothermia with hemicraniectomy, gene therapy and protein therapy is briefly discussed. Furthermore, those combinations that have been studied in a clinical setting are also reviewed.

Keywords: Acute ischemic stroke, clinical, combination therapy, experimental, human, hypothermia, neuroprotection, rodent.

INTRODUCTION

Following an ischemic stroke (IS), intravenously (i.v.) injected recombinant tissue plasminogen activator (rt-PA) reduces the size of ischemic damage and salvages neuronal cells by dissolving the clot obstructing a cerebral artery [1]. Unfortunately, this drug needs to be administered within a therapeutic window of 4.5 h after symptom onset [2, 3], otherwise hemorrhagic complications increase [4]. Another therapeutic strategy is “neuroprotection”, which is defined as any strategy, or combination of strategies, that antagonizes, interrupts or slows the propagation of the pathological events that occur following an IS [5]. Abrupt deprivation of oxygen and glucose to neuronal tissue triggers a series of pathological events leading to cell death. This series of destructive events is referred to as an ischemic cascade and can be summarized as cellular bio-energetic failure due to focal cerebral hypoperfusion, followed by excitotoxicity, oxidative stress, blood-brain-barrier (BBB) dysfunction, ischemia-induced microvascular injury, hemostatic activation, post-ischemic inflammation and finally death of neurons, glial and endothelial cells [6-10]. In the last two decades, neuroprotective agents, designed to block this cascade, have been investigated in animal models of cerebral ischemia. The most promising neuroprotectant so far is therapeutic hypothermia (TH), defined as an intentionally induced, controlled reduction of the body temperature below 36°C [11, 12]. The success of this therapy can be explained by its multifaceted neuroprotective effect [13]. It retards energy depletion by lowering the metabolic and the enzymatic rate [14], restores the neurotransmitter balance [15], reduces the intracellular calcium influx, reduces intracellular acidosis [16], suppresses reactive oxygen species (ROS) formation [17], suppresses infiltration of inflammatory cells [18], prevents BBB disruption [19], suppresses specific cell death pathways or up-regulates cell survival mechanisms [11, 20-22]. However, its beneficial effect is still not completely known [23] and researchers tend to further improve its salvageable beneficial effect by combining it with other neuroprotective strategies. This review will summarize which neuroprotective strategies have already been combined with TH in rodent models of focal cerebral ischemia. A distinction is made between those drugs interrupting only one event of the ischemic cascade and those mitigating different pathways and thereby having multimodal effects. Also the combination of TH with hemicraniectomy, gene therapy and protein therapy is briefly discussed. Furthermore, those combinations tested in a clinical setting are also reviewed and discussed.

Although there are some articles reviewing combination therapies with TH [24, 25], this review is the first to provide a complete overview of all combination strategies with TH in rodent models of IS as well as in a clinical setting. Moreover, the mechanisms involved are detailed. A summary can be found in Table 1.

Table 1.

Summary of all neuroprotective strategies that have been combined with therapeutic hypothermia for the treatment of ischemic stroke.

Reference Model Therapeutic Hypothermia – Target Temperature (°C) Second Neuroprotective Strategy Is Combination Therapy More Neuroprotective than Monotherapy?
[30] Hypotensive rat model of bilateral carotid artery occlusion 30 dextromethorphan (20 mg/kg i.p.) yes
[31] Permanent rat MCAO model 33 MK-801 (dizocilpine) (1 mg/kg) no
[34] Permanent rat MCAO model 35 magnesium (IV loading dose of 360 µmol/kg followed by a 25 h i.v. infusion at 120 µmol/kg/h) yes
[35] Temporal rat MCAO model 33-34 magnesium sulfate solution
(15 °C, 120 mg/kg)
yes
[36] Permanent rat MCAO model 35 magnesium (360 µmol/kg) no
[41] Temporal rat MCAO model 34 N-acetyl-aspartyl-glutamate (NAAG) (10 mg/kg i.p.) no
[50] Temporal rat MCAO model 35 3-methyl-1-phenyl-pyrazolin-5-one (edaravone, 3 mg/kg) yes
[53] Temporal mouse MCAO model 33 rt-PA (10 mg/kg i.v.) yes
[54] Rat thromboembolic stroke model 34 rt-PA (10 mg/kg) yes
[55] Rat model of embolic stroke 32 rt-PA (20 mg/kg i.v.) no
[56] Rat model of thromboembolic occlusion 33 rt-PA (1 mg/100 g) no
[57] Clinical study 32-34 rt-PA (0.9 mg/kg) no
[58] Clinical study 33 rt-PA (0.9 mg/kg) no
[65] Temporal rat MCAO model 35 argatroban (3 mg/kg) yes
[69] Temporal rat MCAO model 32-33 atorvastatin pretreatment
(1 mg/kg/day, for 10 days before ischemia)
yes
[77] Temporal rat MCAO model 35 FK506 (tacrolimus) (0.3 mg/kg) yes
[78] Temporal rat MCAO model 32-34 ketoprofen (10 mg/kg) no
[86] Temporal rat MCAO model 34 citicoline (400 mg/kg i.p.) yes
[94, 95] Permanent rat focal embolic stroke model 34 minocycline (45 mg/kg on the first day and 22.5 mg/kg 24 h and 32 h after stroke) no
[96] Temporal rat MCAO model 33 minocycline (twice daily 30 mg/kg) yes
[101] Temporal rat MCAO model 35 caffeinol (ethanol 0.32 g/kg + caffeine 10 mg/kg) yes
[106] Clinical study 33-35 caffeinol (8-9 mg/kg caffeine + 0.4 g/kg ethanol) + rt-PA
(0.9 mg/kg i.v.)
combination could not be evaluated as no control group was included
[132] Temporal rat MCAO model 36 xenon (30%) yes
[145] Temporal rat MCAO model 33 magnesium (1 mmol/kg) and tirilazad (3 mg/kg) yes
[146] Permanent rat MCAO model 33 magnesium ( 2x1 mM/kg) + tirilazad (2x3 mg/kg) yes
[147] Temporal rat MCAO model 33 magnesium (2x1 mmol/l/kg) + tirilazad (2x3 mg/kg) yes
[157] Temporal rat MCAO model 33 mannitol (1 g/kg) no
[158] Hypertensive rabbit model of temporary focal ischemia 33-34 mannitol (1 g/kg) no
[162] Temporal rat MCAO model 33 methohexital (started at a dose of 1 to 1.5 mg/kg/min until an EEG burst-suppression pattern was reached, burst suppression was maintained by an infusion rate of 0.4 to 0.6 mg/kg/min) no
[166] Permanent rat MCAO model 33 brain-derived neurotrophic factor (BDNF) (300 µg/kg/h) yes
[173] Temporal rat MCAO model 30
local cooling
cold albumin solution
(0 °C, 0.5 g/kg)
yes
[175] Permanent rat MCAO model 32 decompressive hemicraniectomy yes
[176] Permanent rat MCAO model 32 decompressive hemicraniectomy yes
[177] Clinical study 35 decompressive hemicraniectomy yes but not significant
[179] Temporal rat MCAO model 33 gene therapy yes
[185] Temporal rat MCAO model 35 protein therapy yes

THERAPEUTIC HYPOTHERMIA IN ISCHEMIC STROKE

Based on the target temperature, TH can be classified into mild (32°C-34°C), moderate (28°C-32°C), deep (11°C-28°C), profound (6°C-10°C) or ultra-profound (< 5°C) hypothermia. However, there has been some inconsistency in defining the range of temperature constituting each level of TH. The ideal therapeutic level is still not known, but most authors currently agreed that a temperature range between 32°C and 34°C is neuro-protective [26].

Furthermore, TH can also be classified based on the moment of institution, i.e. prior to the insult (protective), during the insult (preservative) or after the insult (resuscitative). In the case of stroke, TH will be induced after the insult (resuscitative TH).

DRUGS INTERRUPTING ONE EVENT OF THE ISCHEMIC CASCADE

NMDA Antagonists

IS starts with severe focal hypoperfusion which restricts oxygen and substrates delivery to cells leading to energy failure, loss of membrane potential and consequently depolarization of neurons and glial cells [9]. After depolarization, large amounts of excitotoxic amino acids, especially glutamate, are released into the synaptic cleft. This massive glutamate release stimulates the postsynaptic N-methyl-D-aspartate (NMDA) receptors allowing Ca2+ influx into neurons. This excess of glutamate release is likely to maintain the activation of these NMDA receptors resulting in further increase of the intracellular calcium concentrations and hence neuronal death [27]. NMDA receptors were therefore considered as potential neuroprotective targets. Various NMDA antagonists have been studied as they limit the subsequent neurodegradative processes through reduction of Ca2+ influx through the NMDA-operated Ca2+ channels [28]. Also their combination with TH, which reduces the ischemia induced release of glutamate [29], has been evaluated.

The first report of an NMDA antagonist combined with TH dates back to the early 90s where dextromethorphan, a non-competitive NMDA antagonist, was shown to be synergistically protective when combined with post-ischemic hypothermia (30°C) in a hypotensive rat model of bilateral carotid artery occlusion [30]. Post-ischemic hypothermia has also been combined with the non-competitive NMDA antagonist MK-801 (dizocilpine) in a rat model of permanent focal ischemia. It appeared that hypothermia (33°C) and MK-801, administered 30 min before MCAO at 1 mg/kg, offer similar cerebroprotective effects when administered separately but do not confer additional cerebroprotection when combined [31].

Other than drugs that antagonize the NMDA receptor, researchers also tested products that enhance the concentration of endogenous NMDA antagonists, such as magnesium. Magnesium is the fourth most abundant cation in the body, essential for cell functions such as preservation of membrane integrity, protein synthesis, energy metabolism, maintenance of ionic gradients and regulation of vascular smooth muscle tone [32]. It has also an anti-excitotoxic property since magnesium ions antagonize calcium entry via NMDA receptors [33]. This has been the rationale for the administration of magnesium as a neuroprotective treatment following cerebral ischemia. In a permanent middle cerebral artery occlusion (MCAO) rat model, Campbell et al. [34] concluded that magnesium (i.v. loading dose of 360 µmol/kg followed by a 25 h i.v. infusion at 120 µmol/kg/h) is not neuroprotective unless it is combined with TH (35°C). In a transient MCAO rat model, Song et al. [35] infused a 15°C magnesium sulfate solution (120 mg/kg), which reduced the temperature of the MCA supplied territory to 33-34°C within 5-10 min after infusion. The authors concluded that the combination of local hypothermia and magnesium is more effective in reducing acute ischemic damage than local hypothermia alone. Meloni et al. [36], on the other hand, could not confirm that a combination of TH at 35°C and magnesium (360 µmol/kg) significantly reduces infarct size in a permanent MCAO rat model.

Another, although indirect, endogenous inhibitor of NMDA receptors is N-acetyl-aspartyl-glutamate (NAAG), an abundant peptide transmitter in the mammalian nervous system, widely co-distributed with glutamate, gamma-aminobutyric acid (GABA) and acetylcholine [37, 38]. NAAG is neuroprotective when administered exogenously at low or moderate doses (2-10 mg/kg intraperitoneally (i.p.)) as it activates group II mGlu receptors that inhibit glutamate releases [39, 40]. In a rat model of transient focal MCAO, it was demonstrated that TH (34°C) combined with NAAG (10 mg/kg i.p.) either 40 min before or 20 min after the insult does not considerably improve ischemic damage [41].

In conclusion, the advantage of NMDA receptor antagonists resides in their excitotoxic inhibitory pathway. One caveat is that, however, it affects also other pathways necessary for normal neuronal function and survival and generates many adverse side effects necessitating dose reduction beneath the potential neuroprotective dose [42-45]. Furthermore, the protective time window for NMDA receptor antagonists is only 1 to 2 h [46], which limits its clinical use [47].

Oxidative Stress Scavengers

When there is an imbalance between free radical production and degradation, oxidative stress occurs. Under normal conditions, endogenous antioxidants scavenge the ROS produced. However, in ischemic conditions these defense mechanisms fail to protect tissue from oxidative damage because of overproduction of ROS and inactivation of antioxidant enzymes [48]. It was therefore suggested that the administration of therapeutic compounds that have the ability to neutralize ROS, could provide neuroprotection. Several antioxidant agents have therefore been investigated as free radical scavenging effect-providing neuroprotectants after an IS. Some of them have also been combined with TH, which is known to attenuate oxidative DNA damage and DNA damage-triggered pro-death signaling events [49]. In a rat model of transient (2 h) focal ischemia, Nito et al. [50] investigated the effect of the antioxidant 3-methyl-1-phenyl-pyrazolin-5-one (edaravone) (3.0 mg/kg), intravenously administered just prior to reperfusion, combined with TH (35°C). It could be concluded that the combined treatment

significantly reduced edema volume and infarct size. When administered separately, edaravone attenuated only brain edema and TH failed to reduce post ischemic brain damage.

Anticoagulants

In acute IS, the endogenous fibrinolysis is usually outweighed by ongoing activation of the coagulation cascade and platelet activation [51]. Components of the coagulation cascade have therefore been attractive targets for neuro-protective agents. rt-PA is currently the only approved treatment for acute IS [52]. Since rt-PA needs to be administered within the first 4.5 h after stroke onset [2, 3], and TH is most effective when initiated as soon as possible after the insult, the question raised whether rt-PA could be combined with TH. In a study by Liu et al. [53], mice subjected to MCAO and receiving rt-PA in hypothermic circumstances (33°C) had smaller infarcts than those receiving rt-PA in normothermic circumstances. In a rat model of thromboembolic stroke, the combination of TH (34°C) with rt-PA treatment, both induced 1.5 h after stroke onset, was superior to thrombolysis alone and resulted in a reduction of infarct volume as well as a mitigation in the breakdown of the BBB [54]. On the other hand, Meden et al. [55] concluded that, although rt-PA and a 3-h TH (32°C) reduced the infarct volume remarkably, the combination did not show any further protection in a rat model of embolic stroke. Similarly, Kollmar et al. [56] could not show an additive effect when rt-PA, administered 1 or 3 h after embolization, was combined with TH (33°C), initiated 1 h after embolization and maintained for 4 h, in a rat model of thromboembolic occlusion of the middle cerebral artery. The safety and efficacy of TH combined with intravenous rt-PA were also investigated in acute IS patients. Based on the National Institutes of Health Stroke Scale (NIHSS) score and the Barthel Index (BI), it was concluded that the combination of TH (32-34°C), induced locally on the surface of the lesion side of the head, and rt-PA (0.9 mg/kg, 10% of the dose as a bolus and the remainder given as a constant infusion over 60 min) provided no benefit compared to rt-PA alone [57]. Also Hemmen et al. [57, 58] could not demonstrate statistically significant differences between hypothermic (33°C) and normothermic patients receiving an rt-PA treatment (0.9 mg/kg) [58]. Nevertheless, both studies indicated that it is safe to combine TH with rt-PA.

Next to rt-PA, argatroban also has been combined with TH. Argatroban directly inhibits free and clot-bound thrombin and, hence, thrombin-induced activities [59]. It has predictable anticoagulant effects [60], causes less bleeding compared to heparin for the same anticoagulant effect [61] and is well-tolerated [62]. It has been shown that argatroban is beneficial in models of acute IS [63, 64]. In an MCAO rat model, Kamiya et al. [65] investigated and confirmed that argatroban (3.0 mg/kg), continuously injected for 24 h after onset of ischemia, combined with TH (35°C), significantly decreased the cortical infarct volume compared with vehicle treated groups and animals treated with only argatroban.

Statins

Improvement in the microcirculation can be achieved by statins or 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, originally introduced as inhibitors of cholesterol biosynthesis, but also exerting neuroprotective effects by up-regulating endothelial nitric oxide (NO) synthase (eNOS) [66]. As nitric oxide relaxes vascular smooth muscle, it increases cerebral blood flow and thus improves microcirculation [67, 68]. Lee et al. [69] demonstrated that atorvastatin pretreatment (1 mg/kg, daily for 10 days before ischemia) enhances the efficacy of neuroprotection conferred by TH (32-33°C) in acute IS. The simultaneous administration of atorvastatin and TH showed a greater reduction of infarct size than each treatment modality alone. Moreover, atorvastatin pretreatment also extended the therapeutic time window of TH from 3 h to 6 h after stroke. As statins are safe and effective drugs, it is an attractive strategy to combine them with TH.

Anti-Inflammatory Agents

In ischemic brain parenchyma, inflammatory reactions are triggered which may amplify further tissue damage by triggering other deleterious mechanisms [70, 71]. Ischemic injury induced inflammation can be characterized by the rapid synthesis of pro-inflammatory cytokines and chemokines and the coordinated infiltration of neutrophils, T-lymphocytes and macrophages [72]. Because inflammation reactions occur rapidly and persist for a few days after ischemic brain injury [73], these responses are potential targets for human therapy.

FK506 or tacrolimus is a drug that suppresses the release of inflammatory cytokines and decreases NO synthase resulting in a reduced production of NO. It has been demonstrated that FK506 provides neuroprotective effects against transient and permanent focal ischemia [74], global ischemia [75] and chronic hypoperfusion [76]. In a rat model of transient MCAO, Nito et al. [77] combined TH (35°C) with FK506 (0.3 mg/kg) and found that TH further reduced the infarct and edema damage. TH also expanded the therapeutic time window for FK506 administration. A low dose of FK506 (0.3 mg/kg) was shown to be neuroprotective when administered at 1 h, but not at 2 h. However, the combination of FK506 and TH significantly improved infarct size and edema volume, even when administered 2 h after MCAO. Although the precise mechanisms of this neuroprotective effect remain unclear, this combination may be useful in future treatment for acute stroke.

Another drug tested was ketoprofen, a non-steroid agent with a very potent analgesic and anti-inflammatory action. At a dose of 10 mg/kg body weight, combined with TH (32-34°C), it was not more effective than the isolated action of these two neuroprotective therapies [78].

Drugs Interrupting Multiple Ischemic Cascades

Next to those agents interrupting only one pathway of the ischemic cascade, there are several agents that have the ability, like TH, to influence numerous pathways simultaneously. Some of these agents have also been combined with TH.

Citicoline

Citicoline is an endogenous compound, originally identified as the key intermediary in the biosynthesis of phosphatidyl-choline [79]. Since it was recognized as a neuroprotectant, it has been used in a plethora of experimental and clinical trials. It has some neuroprotective ability to improve phosphatidyl-choline synthesis in the injured brain [80]. It stabilizes membrane function [81], reduces free radical formation [82, 83], inhibits free fatty acid release [84] and it may also interact with the apoptotic cascade by inhibiting pro-caspase expression and caspase activation [85]. Sahin et al. [86] investigated the effect of citicoline (400 mg/kg i.p.) combined with TH (34 °C) in a rat model of transient focal cerebral ischemia. The authors concluded that the combination therapy is more effective in mitigating cerebral damage than either therapy used alone. The combination resulted in a greatly reduced expression of the tested apoptotic proteins; it also significantly affected the expression of the anti-apoptotic protein Bcl-2 and reduced apoptotic cell death, thus preventing neuronal damage.

Minocycline

Minocycline is a second-generation tetracycline which easily crosses the BBB [87]. Besides its antimicrobial action, it has also neuroprotective properties through inhibition of microglial activation [88, 89], attenuation of apoptosis [90], suppression of free-radical production [91] and inhibition of matrix metalloproteinases (MMPs) [92, 93]. Two research groups investigated the combination of minocycline and TH. In a permanent focal embolic stroke model, it was demonstrated that TH (34°C) combined with minocycline, administered i.p. at 1 h and 4 h after embolization on the first day (45 mg/kg body weight), and again after 24 h and 32 h (22.5 mg/kg), reduced infarct volume [94, 95]. However, there was no additive effect compared to the group receiving minocycline alone. Moreover, the group that received only TH, showed no reduction in infarct size compared to the control group [94, 95]. It was suggested this might be due to the insufficient duration of hypothermia, i.e. only 2 h. Therefore, Nagel et al. [96] investigated, in a transient MCAO model, the effect of a prolonged hypothermic phase (4 h, 33 °C) combined with minocycline, administered twice daily (30 mg/kg). They concluded that the combined therapy was only slightly superior to either treatment alone. Nevertheless, since minocycline has only minimal side effects and is well tolerated in humans, it could be a useful drug to treat stroke patients.

Caffeinol

Caffeine (1,3,7-trimethyxantine) and ethanol are among the most widely and frequently used psychoactive drugs in most societies. Both are rapidly absorbed from the gastrointestinal tract achieving high concentrations in the brain via the blood stream. Caffeine is a competitive antagonist at the adenosine receptor. Its chronic administration up-regulates the brain adenosine receptor [97]. This receptor up-regulation, in combination with increased brain adenosine

concentrations produced in response to ATP breakdown during ischemia, could increase stimulation of inhibitory adenosine transduction pathways resulting in neuro-protection [98]. Ethanol, on the other hand, acts on the brain via GABAA receptor stimulation and inhibition of NMDA receptors [99]. It was shown to reduce neuronal death in a gerbil model of global ischemia [100].

Aronowski et al. [101] demonstrated that caffeinol, a mixture of ethanol (0.32 g/kg) and caffeine (10 mg/kg), combined with intra-ischemic TH (35 °C), initiated 1 h after a 2.5 h transient MCAO, enhanced the neuroprotective effect of caffeinol or TH alone by >50%. They also demonstrated that it is very important to apply ethanol and caffeine at the same time in order to achieve optimal neuroprotection. Animals that were treated with ethanol and 2 h later with caffeine showed no benefit [101]. However, despite the positive effects of caffeinol, a disadvantage is the development of tolerance to its neuroprotective effect. Adenosine receptors are known to desensitize rapidly in response to repetitive activation [102]. Analogously, repetitive treatment with ethanol up-regulates N-methyl-D-aspartate (NMDA) receptor activity, down-regulates GABAA receptor function [103] and potentiates susceptibility to glutamate excitotoxicity [104]. Daily administration of caffeinol, for 2 to 3 weeks, before stroke builds up a tolerance to its neuroprotective properties [105]. In a study by Martin-Schild et al. [106], it was demonstrated that it is feasible to combine a 2 h caffeinol infusion (caffeine 8-9 mg/kg + ethanol 0.4 g/kg), started 4 h after symptom onset, and TH (33-35 °C, started 5 h after symptom onset) in patients with acute stroke treated with rt-PA. No adverse events were attributed to caffeinol and there was no apparent increase in brain hemorrhage by linking caffeinol and cooling to rt-PA. However, as no control group was included in the study, the efficacy of the combination therapy could not be evaluated.

Xenon

Xenon, a noble gas with anesthetic properties, provides neuroprotection in experimental models of neonatal asphyxia [107, 108], focal IS [109-111], cardiopulmonary bypass [112] and cardiac arrest [113]. It is known to interact with the adenosine triphosphate potassium channel [114, 115] and the glutamatergic NMDA receptor [116-118]. In addition, xenon may also be neuroprotective by reducing overall neurotransmitter release [119], inhibition of the α-amino-3-hydroxy-5-methyl-4-isoxazolole propionate and kainate receptors, which are 2 subtypes of glutamate receptor channels [120], reduction in cytosolic pro-apoptotic Bax protein expression and enhanced Bcl-xL expression [121-123], activation of 2-pore domain K+ channels [124], inhibition of calcium/calmodulin-dependent protein kinase II [119], and increased phosphorylation of transcription factor cAMP-response element binding protein, which may, in turn, up-regulate cAMP-response element binding protein-dependent pro-survival genes [125, 126]. Since TH and xenon have been shown to have both anti-excitotoxic [127, 128] and anti-apoptotic properties [129-131], the combination has been studied in a rat model of temporary focal ischemia [132]. The results showed that xenon (30%) and TH (36°C) exhibit synergistic neuroprotective properties when administered together. Xenon may thus be a promising agent with effective neuroprotective properties and has no adverse effects when administered at sub-anesthetic concentrations [109, 110, 112]. However, there are two drawbacks related to the use of xenon. First, it is described that xenon inhibits tPA thrombolysis and should only be administered after tPA-induced reperfusion [133]. Second, xenon delivery capability systems are currently very expensive, making their wide use less probable.

Magnesium and Tirilazad

Magnesium is a naturally occurring calcium antagonist that promotes vasodilation of cerebral arteries [134]. Magnesium ions (Mg2+) participate in a voltage-sensitive blockade of ion channels, resulting in a non-competitive antagonism of NMDA receptors [33, 134]; they compete with extracellular calcium ions to reduce calcium entry into cells [135] and inhibit the release of intracellular calcium ions [136] and excitatory amino acids [137]. The 21-aminosteroid tirilazad mesylate, on the other hand, is a free radical scavenger and lipid peroxidation inhibitor [138]. Both drugs have been shown to have beneficial effects in numerous animal studies of focal and global cerebral ischemia [139, 140], traumatic brain injury [141], subarachnoid hemorrhage [142] and spinal cord ischemia [143]. Also the combination of these pharmacological agents has been shown to be synergistically neuroprotective in a rat model of transient focal cerebral ischemia [144]. Schmid-Elsaesser et al. [145] investigated the effect of TH (33°C) combined with tirilazad (3 mg/kg) and magnesium (MgCl2, 1 mmol/kg), administered both before and after ischemia, in rats subjected to MCAO for 90 min and concluded that the combination significantly reduced infarct size. Even in a model of permanent focal cerebral ischemia of 6 h, the combined therapy provided neuroprotection [146]. In a follow-up paper, Zausinger et al. [147] defined the therapeutic window of this combination and concluded that, in a temporal MCAO rat model (90 min), this therapeutic strategy is even efficient when applied up to 3 h after the ischemic insult.

Mannitol

Mannitol has neuroprotective properties in transient [148] and permanent MCAO models [149, 150] as well as in models of hemorrhagic stroke [151]. It is a hypertonic agent that reduces blood viscosity up to 2 h after i.v. administration [152] and thus improves cerebral blood flow in ischemic situations [153, 154]. It also reduces cerebral edema because of its osmotic effect [155] and acts as a free-radical scavenger [156]. The combination of mannitol with TH was evaluated by Karibe et al. [157] who concluded that, in a rat model of transient focal ischemia, mannitol (25%, 1 g/kg) added no significant protection to TH (33°C). Also in a hypertensive rabbit model of temporary focal ischemia, mannitol (1 g/kg of body weight) combined with TH (33-34°C) did not result in significantly smaller infarct volumes compared with the individual therapies [158]. The use of mannitol in combination with TH is therefore not indicated. Furthermore, as the effects of mannitol change with time after administration, it is an unsuitable agent to use. It was found that within 30 min of administration, intracranial pressure (ICP) drops followed by an increase in ICP secondary to a rebound effect [159, 160].

Methohexital

The protective properties of barbiturates include stabilization of cell membranes, improvement of blood flow into the ischemic brain tissue as well as counteraction of oxidative and excitotoxic processes, resulting in an inhibition of intracellular calcium overload [161]. Westermaier et al. [162] studied whether methohexital, a barbiturate, provides an additional protective effect under hypothermic conditions. Sodium methohexital infusion started 30 min before ischemia at a dose of 1 to 1.5 mg/kg/min until an EEG burst-suppression pattern. Next, it was kept at an infusion rate of 0.4 to 0.6 mg/kg/min. TH (33 °C) was also induced 30 min before the ischemic insult. Although the total infarct volumes were significantly smaller in TH vehicle-treated animals and in TH methohexital-treated animals, compared with normothermic vehicle-treated controls and normothermic methohexital-treated animals, the barbiturate therapy did not provide a significant additional protection under hypothermic conditions [162].

Brain-Derived Neurotrophic Factor

Brain-derived neurotrophic factor (BDNF) is a well-characterized neurotrophic factor which plays an important role in proliferation, differentiation, maintenance, plasticity, survival and function of neurons in the central and peripheral nervous system [163]. Considering its actions, several studies reported a neuroprotective effect in various ischemia models. In a rat model of temporary focal cerebral ischemia, administration of BDNF through an intraventricular route [164], as well as intravenously [165], has been shown to reduce infarct size and improve neurological outcome. Potential mechanisms of the neuroprotective role of BDNF in focal cerebral ischemia include counter-regulation of Bax and Bcl-2 proteins within the ischemic penumbra [165]. However, the exact mechanisms are still under debate. Berger et al. [166] investigated, in a rat model of IS, whether TH (33°C) and intravenous administration of BDNF at 300 µg/kg/h for 2 h, applied 30 min after stroke onset, acted synergistically. They concluded that, when applied separately, TH and BDNF reduced infarct size by 20% and 19%, respectively. However, the combined strategy reduced the infarct size by approximately 40% as compared to non-treated control animals. Both therapies seem to reduce glutamate and the extracellular accumulation of endogenous BDNF. Important to notice is that the BDNF dose used in this study was rather high, i.e. 300 µg/kg/h, compared to studies where BDNF was administered intraventricularly [164] or when other growth factors were used to treat focal cerebral ischemia [167]. The authors mention to have chosen this dose since lower daily doses of 60-80 µg/d were not neuroprotective when given intravenously after transient forebrain ischemia. This may be explained by the fact that, after peripheral delivery, exogenous BDNF may encounter two major obstacles in arriving at the central nervous system, i.e. degradation during circulation in blood and the presence of the BBB which limits transport of BDNF to the brain [168]. Surprisingly, in that study, it seems that TH does not influence the level of endogenous BDNF. Also in a rat model of global ischemia [169] and a pig model of hypoxic ischemic (HI) brain injury [170], it has been shown that endogenous BDNF levels remain unaltered by TH.

Albumin

Albumin is an endogenous plasma protein with neuroprotective properties. It is known to protect both parenchymal and vascular elements of the brain, diminish brain edema, maintain microvascular integrity, inhibit endothelial cell apoptosis and exert antioxidant effects [171]. However, both moderate and high-dose systemic human albumin therapies have been shown to cause severe dose-related adverse effects in clinical stroke studies [172]. Therefore, Chen et al. [173] investigated the neuroprotective effect of low-dose albumin (0.5 g/kg), infused locally at the ischemic site, in a rat model of 2 h MCAO. By infusing albumin as a cold (0°C) solution, it was furthermore possible to induce local brain hypothermia. Temperature was significantly reduced within 3 min in the cerebral cortex and the striatum (from ± 37°C to ± 30°C) and the reduced temperature was sustained up to 45 min. The local low-dose cold albumin infusion into the ischemic area, which offered a combination of regional brain hypothermia and albumin administration, resulted in a significant reduction in infarct volume and a significant improvement in neurological and motor function. This method has the potential to be used in a clinical setting as it has the advantage that cooled low doses of albumin can be infused, which reduces the risk of systemic adverse dose-related effects. Furthermore, it produces local TH much faster than systemically induced whole body TH. However, the local infusion of albumin in human brain is very invasive and risky as well as the long-term neuroprotective effect of this strategy in animal models remains to be investigated.

DECOMPRESSIVE CRANIECTOMY

Regardless of the underlying pathology, all types of stroke are accompanied with brain edema. Because the brain is encased by the walls of the bony skull, this swelling leads to an increased ICP and results in an enlarged area of brain damage. Craniectomy, a technique in which a portion of the skull is removed and the dura is opened, is one of the most effective ways to relieve the increased ICP secondary to cerebral edema following IS [174]. The effect of combined decompressive craniectomy and TH was first investigated by Doerfler et al. [175]. In a rat model of permanent MCAO, it was demonstrated that craniectomy combined with TH (32°C, maintained for 5 h), yields a significant additional benefit as the combination resulted in additional reduction in infarct size and improvement in neurological outcome compared with controls. Using the same model, Jieyong et al. [176] demonstrated that the combined therapy up-regulates Bcl-2, an anti-apoptotic protein, and down-regulates Bax, a pro-apoptotic protein, resulting in a reduction in cell apoptosis and infarct size.

This combination strategy was also evaluated in patients with malignant supratentorial cerebral ischemia [177]. It seemed that patients who received a combination of TH (35°C) and hemicraniectomy performed better compared to patients who were treated with decompressive hemicraniectomy alone [177]. However, the difference was not statistically significant, due to the small sample size, and therefore, no definitive conclusions could be drawn.

GENE THERAPY

A novel therapeutic strategy to treat IS is gene therapy or the transfer of genetic material into host cells with the intention of expressing the protein of interest. It is known that cerebral ischemia alters the expression of many genes. Those genes possessing neuroprotective properties may thus be ideal candidates for gene therapy.

Lawrence et al. [178] showed that overexpression of the anti-apoptotic protein Bcl-2 prevents apoptosis and improves striatal neuron survival when delivered 1.5 h after stroke. When delivered 5 h after stroke, no protection was observed. However, post-ischemic TH (33°C) prolonged the therapeutic window for Bcl-2 gene therapy from 1.5 to 5h, and Bcl-2 plus TH blocked cytochrome c release 48 h after the ischemia onset. These data demonstrate a synergistic effect of TH and Bcl-2 overexpression, suggesting a potential clinical application of TH combined with gene therapy [179].

PROTEIN THERAPY

Gene therapy may be a potential treatment strategy to improve stroke related brain damage. However, it takes considerable time to deliver a gene of interest into the brain and to express a sufficient amount of therapeutic proteins. As an alternative approach, delivering therapeutic proteins directly to ischemic brain tissue has been proposed [180]. This is possible through protein transduction domains (PTDs), which are small peptides that are able to ferry much larger molecules into cells independent of classical endocytosis [181]. PTDs have made it possible to design strategies for delivering pharmacologically potent macro-molecules and even active enzymes to brain tissue by crossing the BBB and cell membranes [182]. One of these macromolecules is FNK, an artificial protein derived from the anti-apoptotic protein Bcl-xL by substituting three amino acids [183]. It is the first mutant with a gain-of-function phenotype among the mammalian anti-apoptotic factors and shows anti-necrotic as well as anti-apoptotic activity [183]. By fusing it with the human immunodeficiency virus type 1/trans-activator of transcription (HIV-TAT) protein transduction domain, it can be transduced into neuronal cells rapidly [184]. The protein transduction domain fused FNK (PTD-FNK) protein has been shown to be significantly protective against rat brain focal ischemia, even when administered 3 h after ischemia [184]. Recently, Sakurazawa et al. [185] evaluated whether PTD-FNK combined with TH (35°C) is more effective than monotherapy in a rat model of MCAO. It could be concluded that a hypothermic PTD-FNK treatment significantly reduces infarct volume compared to a normothermic PTD-FNK treatment [185]. The combined therapy is thus an effective and safe strategy for neuronal protection against cerebral ischemia.

COMBINATION THERAPY TESTED IN NEONATAL RATS

Several of the combination treatments mentioned above were also tested in a neonatal rat model of HI brain injury. HI injury is a devastating complication in childbirth [186] that occurs at a frequency of 1-4 per 1,000 live births [187]. It causes long-term neurological and behavioral impairment in the developing brain. To date, hypothermia is the only intervention that improves outcome. As with stroke, several research groups evaluated whether a second intervention could augment the protection afforded by TH.

Ma et al. [131] demonstrated that concurrent administration of xenon (20%) and TH (35 °C) synergistically reduced long-term damage in a rat model of neonatal asphyxia. In a follow-up study, the authors also concluded that even asynchronous administration of xenon and hypothermia at a 1 h interval could produce a significant reduction in infarct volume [123]. The combination was also evaluated by Hobbs et al. [188] who concluded that xenon (50%) and TH (32°C) additively confer greater protection than either treatment alone. These findings are in accordance with the study of Sheng et al. [132], who demonstrated that xenon (30%) and TH (36°C) exhibit synergistic neuroprotective properties when administered together in a temporal rat MCAO model.

Another combination that was tested in neonatal rats was TH plus MK-801. Ikonomidou et al. [189] concluded that lowering the body temperature by 2.5 °C together with MK-801 pretreatment provides total protection against HI brain damage in infant rat pups. Also Alkan et al. [190] demonstrated that, in a rat HI model, the combined treatment significantly reduced mortality rate and offered better protection in terms of neuron survival. However, these findings are in contrast with those of Frazzini et al. [31] who evaluated the neuroprotective effect of this combination in a rat MCAO model but could not demonstrate an additive degree of cerebroprotection. This finding demonstrates that the results depend on the model used.

CONCLUSION

A better understanding of the underlying patho-physiology of IS has led to the development of several pharmacological and non-pharmacological neuroprotective agents. Despite the promising results in experimental studies, not all success at the bench has translated to success at the bedside [191]. Therefore, the development of additional acute stroke therapies represents a large unmet need with many remaining challenges but also opportunities to incorporate novel approaches [192]. Because of the poor response to the neuroprotective monotherapy, several research groups have evaluated the neuroprotective potential of combination therapies. As TH is currently the most promising neuroprotective strategy, it is an ideal candidate to combine with other neuroprotective compounds. Of all agents summarized in this review, dextromethorphan, edaravone, argatroban, atorvastatin, tacrolimus, citicoline, BDNF, albumin and magnesium, whether or not combined with tirilazad, were found to be synergistically protective when combined with TH in rodent models of acute IS. However, their neuroprotective potential still needs to be confirmed in clinical trials. To date, only rt-PA, caffeinol and decompressive hemicraniectomy have been combined with TH in IS patients. Unfortunately, no definitive conclusions concerning the efficacy of these treatment strategies can be drawn yet. Further researches, both experimental and clinical, are needed.

ACKNOWLEDGEMENTS

Goossens J. drafted the manuscript. Hachimi-Idrissi S. contributed to the design as well as the correction of the manuscript.

CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest.

REFERENCES

  • 1.Goldstein L B. Acute ischemic stroke treatment in 2007. Circulation. 2007;116(13):1504–1514. doi: 10.1161/CIRCULATIONAHA.106.670885. [DOI] [PubMed] [Google Scholar]
  • 2.Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees K R, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D, Investigators E. Thrombolysis with alteplase 3 to 4. hours after acute ischemic stroke. N. Engl. J. Med. 2008;359(13):1317–1329. doi: 10.1056/NEJMoa0804656. [DOI] [PubMed] [Google Scholar]
  • 3.Lees K R, Bluhmki E, von Kummer R, Brott T G, Toni D, Grotta J C, Albers G W, Kaste M, Marler J R, Hamilton S A, Tilley B C, Davis S M, Donnan G A, Hacke W, Ecass A N, Group E r-P S, Allen K, Mau J, Meier D, del Zoppo G, De Silva D A, Butcher K S, Parsons M W, Barber P A, Levi C, Bladin C, Byrnes G. Time to treatment with intravenous alteplase and outcome in stroke an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727):1695–1703. doi: 10.1016/S0140-6736(10)60491-6. [DOI] [PubMed] [Google Scholar]
  • 4.Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne M H, Hennerici M. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke.The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274(13):1017–1025. [PubMed] [Google Scholar]
  • 5.Ginsberg MD. Neuroprotection for ischemic stroke past, present and future. Neuropharmacology. 2008;55(3):363–389. doi: 10.1016/j.neuropharm.2007.12.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Brouns R, De Deyn P P. The complexity of neurobiological processes in acute ischemic stroke. Clin. Neurol. Neurosurg. 2009;111(6):483–495. doi: 10.1016/j.clineuro.2009.04.001. [DOI] [PubMed] [Google Scholar]
  • 7.Doyle K P, Simon R P, Stenzel-Poore M P. Mechanisms of ischemic brain damage. Neuropharmacology. 2008;55(3):310–318. doi: 10.1016/j.neuropharm.2008.01.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Durukan A, Tatlisumak T. Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol. Biochem. Behav. 2007;87(1):179–197. doi: 10.1016/j.pbb.2007.04.015. [DOI] [PubMed] [Google Scholar]
  • 9.Dirnagl U, Iadecola C, Moskowitz M A. Pathobiology of ischaemic stroke an integrated view. Trends Neurosci. 1999;22(9):391–397. doi: 10.1016/s0166-2236(99)01401-0. [DOI] [PubMed] [Google Scholar]
  • 10.Hossmann KA. Pathophysiology and therapy of experimental stroke. Cell. Mol. Neurobiol. 2006;26(7-8):1057–1083. doi: 10.1007/s10571-006-9008-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Lyden P D, Krieger D, Yenari M, Dietrich W D. Therapeutic hypothermia for acute stroke. Int. J. Stroke. 2006;1(1):9–19. doi: 10.1111/j.1747-4949.2005.00011.x. [DOI] [PubMed] [Google Scholar]
  • 12.So H Y. Therapeutic hypothermia. Korean J. Anesthesiol. 2010;59(5):299–304. doi: 10.4097/kjae.2010.59.5.299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Gupta R, Jovin T G, Krieger D W. Therapeutic hypothermia for stroke do new outfits change an old friendκ Expert Rev. Neurother. 2005;5(2):235–246. doi: 10.1586/14737175.5.2.235. [DOI] [PubMed] [Google Scholar]
  • 14.Lanier W L. Cerebral Metabolic-Rate and Hypothermia - Their Relationship with Ischemic Neurologic Injury. J. Neurosurg. Anesthesiol. 1995;7(3):216–221. doi: 10.1097/00008506-199507000-00021. [DOI] [PubMed] [Google Scholar]
  • 15.Busto R, Globus M Y, Dietrich W D, Martinez E, Valdes I, Ginsberg M D. Effect of mild hypothermia on ischemia-induced release of neurotransmitters and free fatty acids in rat brain. Stroke. 1989;20(7):904–910. doi: 10.1161/01.str.20.7.904. [DOI] [PubMed] [Google Scholar]
  • 16.Busto R, Globus M Y, Dietrich W D, Martinez E, Valdes I, Ginsberg M D. Effect of Mild Hypothermia on Ischemia-Induced Release of Neurotransmitters and Free Fatty-Acids in Rat-Brain. Stroke. 1989;20(7):904–910. doi: 10.1161/01.str.20.7.904. [DOI] [PubMed] [Google Scholar]
  • 17.Globus M Y, Alonso O, Dietrich W D, Busto R, Ginsberg M D. Glutamate release and free radical production following brain injury: effects of posttraumatic hypothermia. J. Neurochem. 1995;65(4):1704–1711. doi: 10.1046/j.1471-4159.1995.65041704.x. [DOI] [PubMed] [Google Scholar]
  • 18.Deng H, Han H S, Cheng D, Sun G H, Yenari M A. Mild hypothermia inhibits inflammation after experimental stroke and brain inflammation. Stroke. 2003;34(10):2495–2501. doi: 10.1161/01.STR.0000091269.67384.E7. [DOI] [PubMed] [Google Scholar]
  • 19.Smith S L, Hall E D. Mild pre- and posttraumatic hypothermia attenuates blood-brain barrier damage following controlled cortical impact injury in the rat. J. Neurotrauma. 1996;13(1):1–9. doi: 10.1089/neu.1996.13.1. [DOI] [PubMed] [Google Scholar]
  • 20.Liu L P, Yenari M A. Clinical application of therapeutic hypothermia in stroke. Neurol. Res. 2009;31(4):331–335. doi: 10.1179/174313209X444099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Krieger D W, Yenari M A. Therapeutic hypothermia for acute ischemic stroke - What do laboratory studies teach usκ. Stroke. 2004;35(6):1482–1489. doi: 10.1161/01.STR.0000126118.44249.5c. [DOI] [PubMed] [Google Scholar]
  • 22.Zhao H, Steinberg G K, Sapolsky R M. General versus specific actions of mild-moderate hypothermia in attenuating cerebral ischemic damage. J. Cereb. Blood Flow Metab. 2007;27(12):1879–1894. doi: 10.1038/sj.jcbfm.9600540. [DOI] [PubMed] [Google Scholar]
  • 23.Zgavc T, Ceulemans A G, Sarre S, Michotte Y, Hachimi-Idrissi S. Experimental and clinical use of therapeutic hypothermia for ischemic stroke opportunities and limitations. Stroke Res. Treat. 2011;2011:689290. doi: 10.4061/2011/689290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Tang X N, Liu L, Yenari M A. Combination therapy with hypothermia for treatment of cerebral ischemia. J. Neurotrauma. 2009;26(3):325–331. doi: 10.1089/neu.2008.0594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Hemmen T M, Lyden P D. Multimodal neuroprotective therapy with induced hypothermia after ischemic stroke. Stroke. 2009;40(3 ) Suppl :S126–128. doi: 10.1161/STROKEAHA.108.533083. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Zeiner A, Holzer M, Sterz F, Behringer W, Schorkhuber W, Mullner M, Frass M, Siostrzonek P, Ratheiser K, Kaff A, Laggner A N. Mild resuscitative hypothermia to improve neurological outcome after cardiac arrest.A clinical feasibility trial. Hypothermia After Cardiac Arrest (HACA) Study Group. Stroke. 2000;31(1):86–94. doi: 10.1161/01.str.31.1.86. [DOI] [PubMed] [Google Scholar]
  • 27.Choi D W. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1988;1(8):623–634. doi: 10.1016/0896-6273(88)90162-6. [DOI] [PubMed] [Google Scholar]
  • 28.Meldrum B. Protection against ischaemic neuronal damage by drugs acting on excitatory neurotransmission. Cerebrovasc. Brain Metab. Rev. 1990;2(1):27–57. [PubMed] [Google Scholar]
  • 29.Mitani A, Kataoka K. Critical levels of extracellular glutamate mediating gerbil hippocampal delayed neuronal death during hypothermia brain microdialysis study. Neuroscience. 1991;42(3):661–670. doi: 10.1016/0306-4522(91)90035-m. [DOI] [PubMed] [Google Scholar]
  • 30.Ginsberg M D, Globus M Y T, Busto R, Dietrich W D, Krieglstein J, Oberpichler H. The Potential of Combination Pharmacotherapy in Cerebral-Ischemia. In Pharmacology Cerebral Ischemia 1990 Stuttgart Germany Wissenschaftliche Verlagsgesellschaft mbh. 1990:499–510. [Google Scholar]
  • 31.Frazzini V I, Winfree C J, Choudhri H F, Prestigiacomo C J, Solomon R A. Mild Hypothermia and Mk-801 Have Similar but Not Additive Degrees of Cerebroprotection in the Rat Permanent Focal Ischemia Model. Neurosurgery. 1994;34(6):1040–1045. doi: 10.1227/00006123-199406000-00013. [DOI] [PubMed] [Google Scholar]
  • 32.Meloni B P, Zhu H, Knuckey N W. Is magnesium neuro- protective following global and focal cerebral ischaemiaκ A review of published studies. Magnes. Res. 2006;19(2):123–137. [PubMed] [Google Scholar]
  • 33.Nowak L, Bregestovski P, Ascher P, Herbet A, Prochiantz A. Magnesium gates glutamate-activated channels in mouse central neurones. Nature. 1984;307(5950):462–465. doi: 10.1038/307462a0. [DOI] [PubMed] [Google Scholar]
  • 34.Campbell K, Meloni B P, Knuckey N W. Combined magnesium and mild hypothermia (35 degrees C) treatment reduces infarct volumes after permanent middle cerebral artery occlusion in the rat at 2 and 4, but not 6 h. Brain Res. 2008;1230:258–264. doi: 10.1016/j.brainres.2008.06.110. [DOI] [PubMed] [Google Scholar]
  • 35.Song W, Wu Y M, Ji Z, Ji Y B, Wang S N, Pan S Y. Intra-carotid cold magnesium sulfate infusion induces selective cerebral hypothermia and neuroprotection in rats with transient middle cerebral artery occlusion. Neurol. Sci. 2013;34(4):479–486. doi: 10.1007/s10072-012-1064-3. [DOI] [PubMed] [Google Scholar]
  • 36.Meloni B P, Cross J L, Brookes L M, Clark V W, Campbell K, Knuckey N W. FAST-Mag protocol with or without mild hypothermia (35 degrees C) does not improve outcome after permanent MCAO in rats. Magnes. Res. 2013;26(2):67–73. doi: 10.1684/mrh.2013.0340. [DOI] [PubMed] [Google Scholar]
  • 37.Coyle J T. The nagging question of the function of N-acetylaspartylglutamate. Neurobiol. Dis. 1997;4(3-4):231–238. doi: 10.1006/nbdi.1997.0153. [DOI] [PubMed] [Google Scholar]
  • 38.Neale J H, Bzdega T, Wroblewska B. N-acetylaspartylglutamate: The most abundant peptide neurotransmitter in the mammalian central nervous system. J. Neurochem. 2000;75(2):443–452. doi: 10.1046/j.1471-4159.2000.0750443.x. [DOI] [PubMed] [Google Scholar]
  • 39.Cai Z W, Lin S Y, Rhodes P G. Neuroprotective effects of N-acetylaspartylglutamate in a neonatal rat model of hypoxia-ischemia. Eur. J. Pharmacol. 2002;437(3):139–145. doi: 10.1016/s0014-2999(02)01289-x. [DOI] [PubMed] [Google Scholar]
  • 40.Pin J P, Duvoisin R. The Metabotropic Glutamate Receptors - Structure and Functions. Neuropharmacology. 1995;34(1):1–26. doi: 10.1016/0028-3908(94)00129-g. [DOI] [PubMed] [Google Scholar]
  • 41.Van Hemelrijck A, Hachimi-Idrissi S, Sarre S, Ebinger G, Michotte Y. Neuroprotective effect of N-acetyl-aspartyl-glutamate in combination with mild hypothermia in the endothelin-1 rat model of focal cerebral ischaemia. J. Neurochem. 2005;95(5):1287–1297. doi: 10.1111/j.1471-4159.2005.03450.x. [DOI] [PubMed] [Google Scholar]
  • 42.Dingledine R, Borges K, Bowie D, Traynelis S F. The glutamate receptor ion channels. Pharmacol. Rev. 1999;51(1):7–61. [PubMed] [Google Scholar]
  • 43.Haberny K A, Paule M G, Scallet A C, Sistare F D, Lester D S, Hanig J P, Slikker W. Ontogeny of the N-methyl-D-aspartate (NMDA) receptor system and susceptibility to neurotoxicity. Toxicol. Sci. 2002;68(1):9–17. doi: 10.1093/toxsci/68.1.9. [DOI] [PubMed] [Google Scholar]
  • 44.Hardingham G E, Bading H. The Yin and Yang of NMDA receptor signalling. Trends Neurosci. 2003;26(2):81–89. doi: 10.1016/S0166-2236(02)00040-1. [DOI] [PubMed] [Google Scholar]
  • 45.Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, Dikranian K, Tenkova T I, Stefovska V, Turski L, Olney J W. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science. 1999;283(5398):70–74. doi: 10.1126/science.283.5398.70. [DOI] [PubMed] [Google Scholar]
  • 46.Gladstone D J, Black S E, Hakim A M. Heart Stroke Foundation of Ontario Centre of Excellence in Stroke, R.Toward wisdom from failure lessons from neuroprotective stroke trials and new therapeutic directions. Stroke. 2002;33(8):2123–2136. doi: 10.1161/01.str.0000025518.34157.51. [DOI] [PubMed] [Google Scholar]
  • 47.Ikonomidou CTL. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injuryκ. Lancet Neurol. 2002;1(6):383–386. doi: 10.1016/s1474-4422(02)00164-3. [DOI] [PubMed] [Google Scholar]
  • 48.Chan P H. Role of oxidants in ischemic brain damage. Stroke. 1996;27(6):1124–1129. doi: 10.1161/01.str.27.6.1124. [DOI] [PubMed] [Google Scholar]
  • 49.Ji X, Luo Y, Ling F, Stetler R A, Lan J, Cao G, Chen J. Mild hypothermia diminishes oxidative DNA damage and pro-death signaling events after cerebral ischemia a mechanism for neuroprotection. Front Biosci. 2007;12:1737–1747. doi: 10.2741/2185. [DOI] [PubMed] [Google Scholar]
  • 50.Nito C, Kamiya T, Amemiya S, Katoh K, Katayama Y. The neuroprotective effect of a free radical scavenger and mild hypothermia following transient focal ischemia in rats. Acta Neurochir. 2003;86(Suppl. ):199–203. doi: 10.1007/978-3-7091-0651-8_43. [DOI] [PubMed] [Google Scholar]
  • 51.Eddleston M, de la Torre J C, Oldstone M B, Loskutoff D J, Edgington T S, Mackman N. Astrocytes are the primary source of tissue factor in the murine central nervous system.A role for astrocytes in cerebral hemostasis. J. Clin. Invest. 1993;92(1):349–358. doi: 10.1172/JCI116573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Grotta J, Marler J. Intravenous rt-PA a tenth anniversary reflection. Surgical Neurol. 2007;68 (1):12–16. doi: 10.1016/j.surneu.2007.07.079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Liu L P, Tang X N, Yenari M A. Mild hypothermia reduces hemorrhage and blood brain barrier (BBB) disruption following tissue plasminogen activator treatment in experimental stroke. Neurology. 2006;66(5):A242–A243. [Google Scholar]
  • 54.Kallmunzer B, Schwab S, Kollmar R. Mild hypothermia of 34 degrees C reduces side effects of rt-PA treatment after thromboembolic stroke in rats. Exp. Transl. Stroke Med. 2012;4(1):3. doi: 10.1186/2040-7378-4-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Meden P, Overgaard K, Pedersen H, Boysen G. Effect of hypothermia and delayed thrombolysis in a rat embolic stroke model. Acta Neurol. Scand. 1994;90(2):91–98. doi: 10.1111/j.1600-0404.1994.tb02686.x. [DOI] [PubMed] [Google Scholar]
  • 56.Kollmar R, Henninger N, Bardutzky J, Schellinger P D, Schabitz W R, Schwab S. Combination therapy of moderate hypothermia and thrombolysis in experimental thromboembolic stroke--an MRI study. Exp. Neurol. 2004;190(1):204–212. doi: 10.1016/j.expneurol.2004.07.006. [DOI] [PubMed] [Google Scholar]
  • 57.Bi M, Ma Q, Zhang S, Li J, Zhang Y, Lin L, Tong S, Wang D. Local mild hypothermia with thrombolysis for acute ischemic stroke within a 6-h window. Clin. Neurol. Neurosurg. 2011;113(9):768–773. doi: 10.1016/j.clineuro.2011.08.010. [DOI] [PubMed] [Google Scholar]
  • 58.Hemmen T M, Raman R, Guluma K Z, Meyer B C, Gomes J A, Cruz-Flores S, Wijman C A, Rapp K S, Grotta J C, Lyden P D, Investigators I CL. Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L) final results. Stroke. 2010;41(10):2265–2270. doi: 10.1161/STROKEAHA.110.592295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Okamoto S, Hijikata-Okunomiya A. Synthetic selective inhibitors of thrombin. Methods Enzymol. 1993;222:328–340. doi: 10.1016/0076-6879(93)22022-8. [DOI] [PubMed] [Google Scholar]
  • 60.Swan S K, Hursting M J. The pharmacokinetics and pharma- codynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy. 2000;20(3):318–329. doi: 10.1592/phco.20.4.318.34881. [DOI] [PubMed] [Google Scholar]
  • 61.Berry C N, Girard D, Lochot S, Lecoffre C. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time. Br. J. Pharmacol. 1994;113(4):1209–1214. doi: 10.1111/j.1476-5381.1994.tb17126.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Kathiresan S, Shiomura J, Jang I K, Argatroban J. Thromb. Thrombolysis. 2002;13(1):41–47. doi: 10.1023/a:1015368126304. [DOI] [PubMed] [Google Scholar]
  • 63.Kawai H, Yuki S, Sugimoto J, Tamao Y. Effects of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J. Pharmacol. Exp. Ther. 1996;278(2):780–785. [PubMed] [Google Scholar]
  • 64.Morris D C, Zhang L, Zhang Z G, Lu M, Berens K L, Brown P M, Chopp M. Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke. Stroke. 2001;32(11):2635–2640. doi: 10.1161/hs1101.097390. [DOI] [PubMed] [Google Scholar]
  • 65.Kamiya T, Nito C, Ueda M, Kato K, Amemiya S, Terashi A, Katayama Y. Mild hypothermia enhances the neuroprotective effects of a selective thrombin inhibitor following transient focal ischemia in rats. Acta Neurochir. 2003;86(Suppl. ):195–198. doi: 10.1007/978-3-7091-0651-8_42. [DOI] [PubMed] [Google Scholar]
  • 66.Laufs U, La Fata V, Plutzky J, Liao J K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97(12):1129–1135. doi: 10.1161/01.cir.97.12.1129. [DOI] [PubMed] [Google Scholar]
  • 67.Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U, Endres M. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke. 2000;31(10):2442–2449. doi: 10.1161/01.str.31.10.2442. [DOI] [PubMed] [Google Scholar]
  • 68.Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz M A, Liao J K. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 1998;95(15):8880–8885. doi: 10.1073/pnas.95.15.8880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Lee S H, Kim Y H, Kim Y J, Yoon B W. Atorvastatin enhances hypothermia-induced neuroprotection after stroke. J. Neurol. Sci. 2008;275(1-2):64–68. doi: 10.1016/j.jns.2008.07.029. [DOI] [PubMed] [Google Scholar]
  • 70.Giulian D. Reactive Glia as Rivals in Regulating Neuronal Survival. Glia. 1993;7(1):102–110. doi: 10.1002/glia.440070116. [DOI] [PubMed] [Google Scholar]
  • 71.Giulian D. Ameboid Microglia as Effectors of Inflammation in the Central-Nervous-System. J. Neurosci. Res. 1987;18(1):155–171. doi: 10.1002/jnr.490180123. [DOI] [PubMed] [Google Scholar]
  • 72.Feuerstein G Z, Liu T, Barone F C. Cytokines inflammation and brain injury role of tumor necrosis factor-alpha. Cerebrovasc. Brain Metab. Rev. 1994;6(4):341–360. [PubMed] [Google Scholar]
  • 73.Becker K J. Inflammation and acute stroke. Curr. Opin. Neurol. 1998;11(1):45–49. doi: 10.1097/00019052-199802000-00008. [DOI] [PubMed] [Google Scholar]
  • 74.Furuichi Y, Katsuta K, Maeda M, Ueyama N, Moriguchi A, Matsuoka N, Goto T, Yanagihara T. Neuroprotective action of tacrolimus (FK506) in focal and global cerebral ischemia in rodents: dose dependency, therapeutic time window and long-term efficacy. Brain Res. 2003;965(1-2):137–145. doi: 10.1016/s0006-8993(02)04151-3. [DOI] [PubMed] [Google Scholar]
  • 75.Ide T, Morikawa E, Kirino T. An immunosuppressant, FK506, protects hippocampal neurons from forebrain ischemia in the mongolian gerbil. Neurosci. Lett. 1996;204(3):157–160. doi: 10.1016/0304-3940(96)12352-1. [DOI] [PubMed] [Google Scholar]
  • 76.Wakita H, Tomimoto H, Akiguchi I, Kimura J. Dose-dependent, protective effect of FK506 against white matter changes in the rat brain after chronic cerebral ischemia. Brain Res. 1998;792(1):105–113. doi: 10.1016/s0006-8993(98)00126-7. [DOI] [PubMed] [Google Scholar]
  • 77.Nito C, Kamiya T, Ueda M, Arii T, Katayama Y. Mild hypothermia enhances the neuroprotective effects of FK506 and expands its therapeutic window following transient focal ischemia in rats. Brain Res. 2004;1008(2):179–185. doi: 10.1016/j.brainres.2004.02.031. [DOI] [PubMed] [Google Scholar]
  • 78.Tirapelli D P D, Carlotti C G, Leite J P, Tirapelli L F, Colli B O. Expression of HSP70 in cerebral ischemia and neuro-protetive action of hypothermia and ketoprofen. Arq. Neuropsiquiatr. 2010;68(4):592–596. doi: 10.1590/s0004-282x2010000400021. [DOI] [PubMed] [Google Scholar]
  • 79.Kennedy E P. The synthesis of cytidine diphosphate choline, cytidine diphosphate ethanolamine, and related compounds. J. Biol. Chem. 1956;222(1):185–191. [PubMed] [Google Scholar]
  • 80.Adibhatla R M, Hatcher J F. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J. Neurosci. Res. 2002;70(2):133–139. doi: 10.1002/jnr.10403. [DOI] [PubMed] [Google Scholar]
  • 81.Trovarelli G, Demedio G E, Dorman R V, Piccinin G L, Horrocks L A, Porcellati G. Effect of Cytidine Diphosphate Choline (Cdp-Choline) on Ischemia-Induced Alterations of Brain Lipid in the Gerbil. Neurochem. Res. 1981;6(8):821–833. doi: 10.1007/BF00965041. [DOI] [PubMed] [Google Scholar]
  • 82.Rao A M, Hatcher J F, Dempsey R J. Lipid alterations in transient forebrain ischemia possible new mechanisms of CDP-choline neuroprotection. J. Neurochem. 2000;75(6):2528–2535. doi: 10.1046/j.1471-4159.2000.0752528.x. [DOI] [PubMed] [Google Scholar]
  • 83.Schabitz W R, Li F, Irie K, Sandage B W, Locke K W, Fisher M. Synergistic effects of a combination of low-dose basic fibroblast growth factor and citicoline after temporary experimental focal ischemia. Stroke. 1999;30(2):427–431 discussion 431-422. doi: 10.1161/01.str.30.2.427. [DOI] [PubMed] [Google Scholar]
  • 84.Weiss G B. Metabolism and Actions of Cdp-Choline as an Endogenous Compound and Administered Exogenously as Citicoline. Life Sci. 1995;56(9):637–660. doi: 10.1016/0024-3205(94)00427-t. [DOI] [PubMed] [Google Scholar]
  • 85.Krupinski J, Ferrer I, Barrachina M, Secades J J, Mercadal J, Lozano R. CDP-choline reduces pro-caspase and cleaved caspase-3 expression, nuclear DNA fragmentation, and specific PARP-cleaved products of caspase activation following middle cerebral artery occlusion in the rat. Neuropharmacology. 2002;42(6):846–854. doi: 10.1016/s0028-3908(02)00032-1. [DOI] [PubMed] [Google Scholar]
  • 86.Sahin S, Alkan T, Temel S G, Tureyen K, Tolunay S, Korfali E. Effects of citicoline used alone and in combination with mild hypothermia on apoptosis induced by focal cerebral ischemia in rats. J. Clin. Neurosci. 2010;17(2):227–231. doi: 10.1016/j.jocn.2009.05.016. [DOI] [PubMed] [Google Scholar]
  • 87.Macdonald H, Kelly R G, Allen E S, Noble J F, Kanegis L A. Pharmacokinetic studies on minocycline in man. Clin. Pharmacol. Ther. 1973;14(5):852–861. doi: 10.1002/cpt1973145852. [DOI] [PubMed] [Google Scholar]
  • 88.Tikka T, Fiebich B L, Goldsteins G, Keinanen R, Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J. Neurosci. 2001;21(8):2580–2588. doi: 10.1523/JNEUROSCI.21-08-02580.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc. Natl. Acad. Sci. U. S. A. 1998;95(26):15769–15774. doi: 10.1073/pnas.95.26.15769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Scarabelli T M, Stephanou A, Pasini E, Gitti G, Townsend P, Lawrence K, Chen-Scarabelli C, Saravolatz L, Latchman D, Knight R, Gardin J. Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac/DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac/DIABLO. J. Am. Coll. Cardiol. 2004;43(5):865–874. doi: 10.1016/j.jacc.2003.09.050. [DOI] [PubMed] [Google Scholar]
  • 91.Morimoto N, Shimazawa M, Yamashima T, Nagai H, Hara H. Minocycline inhibits oxidative stress and decreases in vitro and in vivo ischemic neuronal damage. Brain Res. 2005;1044(1):8–15. doi: 10.1016/j.brainres.2005.02.062. [DOI] [PubMed] [Google Scholar]
  • 92.Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan P H, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. U.S.A. 1999;96(23):13496–13500. doi: 10.1073/pnas.96.23.13496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Yong V W, Wells J, Giuliani F, Casha S, Power C, Metz L M. The promise of minocycline in neurology. Lancet Neurol. 2004;3(12):744–751. doi: 10.1016/S1474-4422(04)00937-8. [DOI] [PubMed] [Google Scholar]
  • 94.Wang C X, Yang T, Noor R, Shuaib A. Delayed minocycline but not delayed mild hypothermia protects against embolic stroke. BMC Neurol. 2002;2:2. doi: 10.1186/1471-2377-2-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Wang C X, Yang T, Shuaib A. Effects of minocycline alone and in combination with mild hypothermia in embolic stroke. Brain Res. 2003;963(1-2):327–329. doi: 10.1016/s0006-8993(02)04045-3. [DOI] [PubMed] [Google Scholar]
  • 96.Nagel S, Su Y, Horstmann S, Heiland S, Gardner H, Koziol J, Martinez-Torres F J, Wagner S. Minocycline and hypothermia for reperfusion injury after focal cerebral ischemia in the rat effects on BBB breakdown and MMP expression in the acute and subacute phase. Brain Res. 2008;1188:198–206. doi: 10.1016/j.brainres.2007.10.052. [DOI] [PubMed] [Google Scholar]
  • 97.Rudolphi KA, Keil M, Fastbom J, Fredholm B B. Ischaemic damage in gerbil hippocampus is reduced following upregulation of adenosine (A1) receptors by caffeine treatment. Neurosci. Lett. 1989;103(3):275–280. doi: 10.1016/0304-3940(89)90112-2. [DOI] [PubMed] [Google Scholar]
  • 98.Miller L P, Hsu C. Therapeutic potential for adenosine receptor activation in ischemic brain injury. J. Neurotrauma. 1992;9(Suppl 2 ):S563–577. [PubMed] [Google Scholar]
  • 99.Lovinger D M, White G, Weight F F. Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science. 1989;243(4899):1721–1724. doi: 10.1126/science.2467382. [DOI] [PubMed] [Google Scholar]
  • 100.Phillis J W, Estevez A Y, O'Regan M H. Protective effects of the free radical scavengers, dimethyl sulfoxide and ethanol, in cerebral ischemia in gerbils. Neurosci. Lett. 1998;244(2):109–111. doi: 10.1016/s0304-3940(98)00139-6. [DOI] [PubMed] [Google Scholar]
  • 101.Aronowski J, Strong R, Shirzadi A, Grotta J C. Ethanol plus caffeine (caffeinol) for treatment of ischemic stroke: preclinical experience. Stroke. 2003;34(5):1246–1251. doi: 10.1161/01.STR.0000068170.80517.B3. [DOI] [PubMed] [Google Scholar]
  • 102.Johansson B, Georgiev V, Lindstrom K, Fredholm B B. A(1) and A(2A) adenosine receptors and A(1) mRNA in mouse brain effect of long-term caffeine treatment. Brain Res. 1997;762(1-2):153–164. doi: 10.1016/s0006-8993(97)00378-8. [DOI] [PubMed] [Google Scholar]
  • 103.Snell L D, Tabakoff B, Hoffman PL. Radioligand binding to the N-methyl-D-aspartate receptor/ionophore complex alterations by ethanol in vitro and by chronic in vivo ethanol ingestion. Brain Res. 1993;602(1):91–98. doi: 10.1016/0006-8993(93)90246-j. [DOI] [PubMed] [Google Scholar]
  • 104.Chandler L J, Sumners C, Crews F T. Ethanol inhibits NMDA receptor-mediated excitotoxicity in rat primary neuronal cultures. Alcohol Clin. Exp. Res. 1993;17(1):54–60. doi: 10.1111/j.1530-0277.1993.tb00726.x. [DOI] [PubMed] [Google Scholar]
  • 105.Strong R, Grotta J C, Aronowski J. Combination of low dose ethanol and caffeine protects brain from damage produced by focal ischemia in rats. Neuropharmacology. 2000;39(3):515–522. doi: 10.1016/s0028-3908(99)00156-2. [DOI] [PubMed] [Google Scholar]
  • 106.Martin-Schild S, Hallevi H, Shaltoni H, Barreto A D, Gonzales N R, Aronowski J, Savitz S I, Grotta J C. Combined neuroprotective modalities coupled with thrombolysis in acute ischemic stroke a pilot study of caffeinol and mild hypothermia. J. Stroke Cerebrovasc. Dis. 2009;18(2):86–96. doi: 10.1016/j.jstrokecerebrovasdis.2008.09.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Dingley J, Tooley J, Porter H, Thoresen M. Xenon provides short-term neuroprotection in neonatal rats when administered after hypoxia-ischemia. Stroke. 2006;37(2):501–506. doi: 10.1161/01.STR.0000198867.31134.ac. [DOI] [PubMed] [Google Scholar]
  • 108.Luo Y, Ma D, Ieong E, Sanders R D, Yu B, Hossain M, Maze M. Xenon and sevoflurane protect against brain injury in a neonatal asphyxia model. Anesthesiology. 2008;109(5):782–789. doi: 10.1097/ALN.0b013e3181895f88. [DOI] [PubMed] [Google Scholar]
  • 109.Homi H M, Yokoo N, Ma D, Warner D S, Franks N P, Maze M, Grocott H P. The neuroprotective effect of xenon administration during transient middle cerebral artery occlusion in mice. Anesthesiology. 2003;99(4):876–881. doi: 10.1097/00000542-200310000-00020. [DOI] [PubMed] [Google Scholar]
  • 110.David H N, Leveille F, Chazalviel L, MacKenzie E T, Buisson A, Lemaire M, Abraini J H. Reduction of ischemic brain damage by nitrous oxide and xenon. J. Cereb. Blood Flow Metab. 2003;23(10):1168–1173. doi: 10.1097/01.WCB.0000087342.31689.18. [DOI] [PubMed] [Google Scholar]
  • 111.Limatola V, Ward P, Cattano D, Gu J, Giunta F, Maze M, Ma D. Xenon preconditioning confers neuroprotection regardless of gender in a mouse model of transient middle cerebral artery occlusion. Neuroscience. 2010;165(3):874–881. doi: 10.1016/j.neuroscience.2009.10.063. [DOI] [PubMed] [Google Scholar]
  • 112.Ma D, Yang H, Lynch J, Franks N P, Maze M, Grocott H P. Xenon attenuates cardiopulmonary bypass-induced neurologic and neurocognitive dysfunction in the rat. Anesthesiology. 2003;98(3):690–698. doi: 10.1097/00000542-200303000-00017. [DOI] [PubMed] [Google Scholar]
  • 113.Schmidt M, Marx T, Gloggl E, Reinelt H, Schirmer U. Xenon attenuates cerebral damage after ischemia in pigs. Anesthesiology. 2005;102(5):929–936. doi: 10.1097/00000542-200505000-00011. [DOI] [PubMed] [Google Scholar]
  • 114.Yamada K, Ji J J, Yuan H, Miki T, Sato S, Horimoto N, Shimizu T, Seino S, Inagaki N. Protective role of ATP-sensitive potassium channels in hypoxia-induced generalized seizure. Science. 2001;292(5521):1543–1546. doi: 10.1126/science.1059829. [DOI] [PubMed] [Google Scholar]
  • 115.Bantel C, Maze M, Trapp S. Noble gas xenon is a novel adenosine triphosphate-sensitive potassium channel opener. Anesthesiology. 2010;112(3):623–630. doi: 10.1097/ALN.0b013e3181cf894a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116.Franks NP, Dickinson R, de Sousa S L, Hall A C, Lieb W R. How does xenon produce anaesthesiaκ. Nature. 1998;396(6709):324. doi: 10.1038/24525. [DOI] [PubMed] [Google Scholar]
  • 117.Natale G, Cattano D, Abramo A, Forfori F, Fulceri F, Fornai F, Paparelli A, Giunta F. Morphological evidence that xenon neuroprotects against N-methyl-DL-aspartic acid-induced damage in the rat arcuate nucleus a time-dependent study. Ann. N Acad. Sci. 2006;1074:650–658. doi: 10.1196/annals.1369.063. [DOI] [PubMed] [Google Scholar]
  • 118.Dickinson R, Peterson B K, Banks P, Simillis C, Martin J C, Valenzuela C A, Maze M, Franks N P. Competitive inhibition at the glycine site of the N-methyl-D-aspartate receptor by the anesthetics xenon and isoflurane evidence from molecular modeling and electrophysiology. Anesthesiology. 2007;107(5):756–767. doi: 10.1097/01.anes.0000287061.77674.71. [DOI] [PubMed] [Google Scholar]
  • 119.Petzelt C P, Kodirov S, Taschenberger G, Kox W J. Participation of the Ca(2+)-calmodulin-activated Kinase II in the control of metaphase-anaphase transition in human cells. Cell. Biol. Int. 2001;25(5):403–409. doi: 10.1006/cbir.2000.0646. [DOI] [PubMed] [Google Scholar]
  • 120.Dinse A, Fohr K J, Georgieff M, Beyer C, Bulling A, Weigt H U. Xenon reduces glutamate-, AMPA-, and kainate-induced membrane currents in cortical neurones. Br. J. Anaesth. 2005;94(4):479–485. doi: 10.1093/bja/aei080. [DOI] [PubMed] [Google Scholar]
  • 121.Green D R, Reed J C. Mitochondria and apoptosis. Science. 1998;281(5381):1309–1312. doi: 10.1126/science.281.5381.1309. [DOI] [PubMed] [Google Scholar]
  • 122.Shindler K S, Latham C B, Roth K A. Bax deficiency prevents the increased cell death of immature neurons in bcl-x-deficient mice. J. Neurosci. 1997;17(9):3112–3119. doi: 10.1523/JNEUROSCI.17-09-03112.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 123.Martin J L, Ma D, Hossain M, Xu J, Sanders R D, Franks N P, Maze M. Asynchronous administration of xenon and hypothermia significantly reduces brain infarction in the neonatal rat. Br. J. Anaesth. 2007;98(2):236–240. doi: 10.1093/bja/ael340. [DOI] [PubMed] [Google Scholar]
  • 124.Gruss M, Bushell T J, Bright D P, Lieb W R, Mathie A, Franks N P. Two-pore-domain K+ channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane. Mol. Pharmacol. 2004;65(2):443–452. doi: 10.1124/mol.65.2.443. [DOI] [PubMed] [Google Scholar]
  • 125.Weber N C, Toma O, Wolter J I, Obal D, Mullenheim J, Preckel B, Schlack W. The noble gas xenon induces pharmacological preconditioning in the rat heart in vivo via induction of PKC-epsilon and p38 MAPK. Br. J. Pharmacol. 2005;144(1):123–132. doi: 10.1038/sj.bjp.0706063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126.Wilson B E, Mochon E, Boxer L M. Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol. Cell. Biol. 1996;16(10):5546–5556. doi: 10.1128/mcb.16.10.5546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127.Wilhelm S, Ma D, Maze M, Franks N P. Effects of xenon on in vitro and in vivo models of neuronal injury. Anesthesiology. 2002;96(6):1485–1491. doi: 10.1097/00000542-200206000-00031. [DOI] [PubMed] [Google Scholar]
  • 128.Tymianski M, Sattler R, Zabramski J M, Spetzler R F. Characterization of neuroprotection from excitotoxicity by moderate and profound hypothermia in cultured cortical neurons unmasks a temperature-insensitive component of glutamate neurotoxicity. J. Cereb. Blood Flow Metab. 1998;18(8):848–867. doi: 10.1097/00004647-199808000-00005. [DOI] [PubMed] [Google Scholar]
  • 129.Bossenmeyer-Pourie C, Koziel V, Daval J L. Effects of hypothermia on hypoxia-induced apoptosis in cultured neurons from developing rat forebrain comparison with preconditioning. Pediatr. Res. 2000;47(3):385–391. doi: 10.1203/00006450-200003000-00017. [DOI] [PubMed] [Google Scholar]
  • 130.Xu L, Yenari M A, Steinberg G K, Giffard R G. Mild hypothermia reduces apoptosis of mouse neurons in vitro early in the cascade. J. Cereb. Blood Flow Metab. 2002;22(1):21–28. doi: 10.1097/00004647-200201000-00003. [DOI] [PubMed] [Google Scholar]
  • 131.Ma D, Hossain M, Chow A, Arshad M, Battson R M, Sanders R D, Mehmet H, Edwards A D, Franks N P, Maze M. Xenon and hypothermia combine to provide neuroprotection from neonatal asphyxia. Ann. Neurol. 2005;58(2):182–193. doi: 10.1002/ana.20547. [DOI] [PubMed] [Google Scholar]
  • 132.Sheng S P, Lei B, James M L, Lascola C D, Venkatraman T N, Jung J Y, Maze M, Franks N P, Pearlstein R D, Sheng H, Warner D S. Xenon neuroprotection in experimental stroke interactions with hypothermia and intracerebral hemorrhage. Anesthesiology. 2012;117(6):1262–1275. doi: 10.1097/ALN.0b013e3182746b81. [DOI] [PubMed] [Google Scholar]
  • 133.David H N, Haelewyn B, Risso J J, Colloc'h N, Abraini J H. Xenon is an inhibitor of tissue-plasminogen activator: adverse and beneficial effects in a rat model of thromboembolic stroke. J. Cereb. Blood Flow Metab. 2010;30(4):718–728. doi: 10.1038/jcbfm.2009.275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 134.Iseri L T, French J H. Magnesium nature's physiologic calcium blocker. Am. Heart J. 1984;108(1):188–193. doi: 10.1016/0002-8703(84)90572-6. [DOI] [PubMed] [Google Scholar]
  • 135.Altura B T, Altura B M. Interactions of Mg and K on cerebral vessels--aspects in view of stroke.Review of present status and new findings. Magnesium. 1984;3(4-6):195–211. [PubMed] [Google Scholar]
  • 136.Huang Q F, Gebrewold A, Altura B T, Altura B M. Mg2+ protects against PCP-induced cerebrovasospasms and vascular damage in rat brain. Magnes. Trace Elem. 1990;9(1):44–46. [PubMed] [Google Scholar]
  • 137.Ghribi O, Callebert J, Verrecchia C, Plotkine M, Boulu R G. Blockers of NMDA-operated channels decrease glutamate and aspartate extracellular accumulation in striatum during forebrain ischaemia in rats. Fundam. Clin. Pharmacol. 1995;9(2):141–146. doi: 10.1111/j.1472-8206.1995.tb00273.x. [DOI] [PubMed] [Google Scholar]
  • 138.Hall E D, McCall J M, Means E D. Therapeutic potential of the lazaroids (21-aminosteroids) in acute central nervous system trauma, ischemia and subarachnoid hemorrhage. Adv. Pharmacol. 1994;28:221–268. doi: 10.1016/s1054-3589(08)60497-4. [DOI] [PubMed] [Google Scholar]
  • 139.Tsuda T, Kogure K, Nishioka K, Watanabe T. Mg2+ administered up to twenty-four hours following reperfusion prevents ischemic damage of the Ca1 neurons in the rat hippocampus. Neuroscience. 1991;44(2):335–341. doi: 10.1016/0306-4522(91)90058-v. [DOI] [PubMed] [Google Scholar]
  • 140.Sena E, Wheble P, Sandercock P, Macleod M. Systematic review and meta-analysis of the efficacy of tirilazad in experimental stroke. Stroke. 2007;38(2):388–394. doi: 10.1161/01.STR.0000254462.75851.22. [DOI] [PubMed] [Google Scholar]
  • 141.McIntosh T K, Vink R, Yamakami I, Faden A I. Magnesium protects against neurological deficit after brain injury. Brain Res. 1989;482(2):252–260. doi: 10.1016/0006-8993(89)91188-8. [DOI] [PubMed] [Google Scholar]
  • 142.Ram Z, Sadeh M, Shacked I, Sahar A, Hadani M. Magnesium sulfate reverses experimental delayed cerebral vasospasm after subarachnoid hemorrhage in rats. Stroke. 1991;22(7):922–927. doi: 10.1161/01.str.22.7.922. [DOI] [PubMed] [Google Scholar]
  • 143.Robertson C S, Foltz R, Grossman R G, Goodman J C. Protection against experimental ischemic spinal cord injury. J. Neurosurg. 1986;64(4):633–642. doi: 10.3171/jns.1986.64.4.0633. [DOI] [PubMed] [Google Scholar]
  • 144.Schmid-Elsaesser R, Zausinger S, Hungerhuber E, Baethmann A, Reulen H J. Neuroprotective effects of combination therapy with tirilazad and magnesium in rats subjected to reversible focal cerebral ischemia. Neurosurgery. 1999;44(1):163–171, discussion 171-162. doi: 10.1097/00006123-199901000-00100. [DOI] [PubMed] [Google Scholar]
  • 145.Schmid-Elsaesser R, Hungerhuber E, Zausinger S, Baethmann A, Reulen H J. Combination drug therapy and mild hypothermia: a promising treatment strategy for reversible, focal cerebral ischemia. Stroke. 1999;30(9):1891–1899. doi: 10.1161/01.str.30.9.1891. [DOI] [PubMed] [Google Scholar]
  • 146.Scholler K, Zausinger S, Baethmann A, Schmid-Elsaesser R. Neuroprotection in ischemic stroke--combination drug therapy and mild hypothermia in a rat model of permanent focal cerebral ischemia. Brain Res. 2004;1023(2):272–278. doi: 10.1016/j.brainres.2004.01.094. [DOI] [PubMed] [Google Scholar]
  • 147.Zausinger S, Scholler K, Plesnila N, Schmid-Elsaesser R. Combination drug therapy and mild hypothermia after transient focal cerebral ischemia in rats. Stroke. 2003;34(9):2246–2251. doi: 10.1161/01.STR.0000083622.65684.21. [DOI] [PubMed] [Google Scholar]
  • 148.Suzuki J, Tanaka S, Yoshimoto T. Recirculation in the acute period of cerebral infarction brain swelling and its suppression using mannitol. Surg. Neurol. 1980;14(6):467–472. [PubMed] [Google Scholar]
  • 149.Little J R. Modification of acute focal ischemia by treatment with mannitol. Stroke. 1978;9(1):4–9. doi: 10.1161/01.str.9.1.4. [DOI] [PubMed] [Google Scholar]
  • 150.Little J R. Treatment of acute focal cerebral ischemia with intermittent, low dose mannitol. Neurosurgery. 1979;5(6):687–691. doi: 10.1227/00006123-197912000-00007. [DOI] [PubMed] [Google Scholar]
  • 151.Kagawa S, Koshu K, Yoshimoto T, Suzuki J. The protective effect of mannitol and perfluorochemicals on hemorrhagic infarction: an experimental study. Surg. Neurol. 1982;17(1):66–70. doi: 10.1016/0090-3019(82)90048-9. [DOI] [PubMed] [Google Scholar]
  • 152.Burke A M, Quest D O, Chien S, Cerri C. The effects of mannitol on blood viscosity. J. Neurosurg. 1981;55(4):550–553. doi: 10.3171/jns.1981.55.4.0550. [DOI] [PubMed] [Google Scholar]
  • 153.Andrews R J, Bringas J R, Muto R P. Effects of mannitol on cerebral blood flow, blood pressure, blood viscosity, hematocrit, sodium, and potassium. Surg. Neurol. 1993;39(3):218–222. doi: 10.1016/0090-3019(93)90186-5. [DOI] [PubMed] [Google Scholar]
  • 154.Meyer F B, Anderson R E, Sundt T M, Yaksh T L. Treatment of experimental focal cerebral ischemia with mannitol.Assessment by intracellular bran pH cortical blood flow, and electroencephalography. J. Neurosurg. 1987; 66(1):109–115. doi: 10.3171/jns.1987.66.1.0109. [DOI] [PubMed] [Google Scholar]
  • 155.Bell B A, Smith M A, Kean D M, McGhee C N, MacDonald H L, Miller J D, Barnett G H, Tocher J L, Douglas R H, Best J J. Brain water measured by magnetic resonance imaging.Correlation with direct estimation and changes after mannitol and dexamethasone. Lancet. 1987;1(8524):66–69. doi: 10.1016/s0140-6736(87)91908-8. [DOI] [PubMed] [Google Scholar]
  • 156.Suzuki J Y T. The effect of mannitol in prolongation of permissible occlusion time of cerebral arteries Clinical data of aneurysm surgery. Neurosurg. Rev. 1979;1:13–19. [Google Scholar]
  • 157.Karibe H, Zarow G J, Weinstein P R. Use of mild intraischemic hypothermia versus mannitol to reduce infarct size after temporary middle cerebral artery occlusion in rats. J. Neurosurg. 1995;83(1):93–98. doi: 10.3171/jns.1995.83.1.0093. [DOI] [PubMed] [Google Scholar]
  • 158.Ogilvy C S, Chu D, Kaplan S. Mild hypothermia, hypertension, and mannitol are protective against infarction during experimental intracranial temporary vessel occlusion. Neurosurgery. 1996;38(6):1202–1209, discussion 1209-1210. doi: 10.1097/00006123-199606000-00030. [DOI] [PubMed] [Google Scholar]
  • 159.Muizelaar J P, Wei E P, Kontos H A, Becker D P. Mannitol causes compensatory cerebral vasoconstriction and vasodilation in response to blood viscosity changes. J. Neurosurg. 1983;59(5):822–828. doi: 10.3171/jns.1983.59.5.0822. [DOI] [PubMed] [Google Scholar]
  • 160.Kotwica Z, Persson L. Effect of mannitol on intracranial pressure in focal cerebral ischemia.An experimental study in a rat. Mater. Med. Pol. 1991;23(4):280–284. [PubMed] [Google Scholar]
  • 161.Smith D S, Rehncrona S, Siesjo B K. Barbiturates as protective agents in brain ischemia and as free radical scavengers in vitro. Acta Physiol. Scand. 1980;492(Suppl. ):129–134. [PubMed] [Google Scholar]
  • 162.Westermaier T, Zausinger S, Baethmann A, Steiger H J, Schmid-Elsaesser R. No additional neuroprotection provided by barbiturate-induced burst suppression under mild hypothermic conditions in rats subjected to reversible focal ischemia. J. Neurosurg. 2000;93(5):835–844. doi: 10.3171/jns.2000.93.5.0835. [DOI] [PubMed] [Google Scholar]
  • 163.Geral C, Angelova A, Lesieur S. From molecular to nanotechnology strategies for delivery of neurotrophins emphasis on brain-derived neurotrophic factor (BDNF). Pharmaceutics. 2013;5(1):127–167. doi: 10.3390/pharmaceutics5010127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 164.Schabitz W R, Schwab S, Spranger M, Hacke W. Intraventricular brain-derived neurotrophic factor reduces infarct size after focal cerebral ischemia in rats. J. Cereb Blood Flow Metab. 1997;17(5):500–506. doi: 10.1097/00004647-199705000-00003. [DOI] [PubMed] [Google Scholar]
  • 165.Schabitz W R, Sommer C, Zoder W, Kiessling M, Schwaninger M, Schwab S. Intravenous brain-derived neurotrophic factor reduces infarct size and counterregulates Bax and Bcl-2 expression after temporary focal cerebral ischemia. Stroke. 2000;31(9):2212–2217. doi: 10.1161/01.str.31.9.2212. [DOI] [PubMed] [Google Scholar]
  • 166.Berger C, Schabitz W R, Wolf M, Mueller H, Sommer C, Schwab S. Hypothermia and brain-derived neurotrophic factor reduce glutamate synergistically in acute stroke. Exp. Neurol. 2004;185(2):305–312. doi: 10.1016/j.expneurol.2003.10.008. [DOI] [PubMed] [Google Scholar]
  • 167.Fisher M, Meadows M E, Do T, Weise J, Trubetskoy V, Charette M, Finklestein S P. Delayed treatment with intravenous basic fibroblast growth factor reduces infarct size following permanent focal cerebral ischemia in rats. J. Cereb Blood Flow Metab. 1995;15(6):953–959. doi: 10.1038/jcbfm.1995.121. [DOI] [PubMed] [Google Scholar]
  • 168.Sakane T, Pardridge W M. Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity. Pharm Res. 1997;14(8):1085–1091. doi: 10.1023/a:1012117815460. [DOI] [PubMed] [Google Scholar]
  • 169.Silasi G, Klahr A C, Hackett M J, Auriat A M, Nichol H, Colbourne F. Prolonged therapeutic hypothermia does not adversely impact neuroplasticity after global ischemia in rats. J. Cereb Blood Flow Metab. 2012;32(8):1525–1534. doi: 10.1038/jcbfm.2012.38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 170.Olson L, Faulkner S, Lundstromer K, Kerenyi A, Kelen D, Chandrasekaran M, Aden U, Olson L, Golay X, Lagercrantz H, Robertson N J, Galter D. Comparison of three hypothermic target temperatures for the treatment of HI HIHI ischemia mRNA level responses of eight genes in the piglet brain. Transl. Stroke Res. 2013;4(2):248–257. doi: 10.1007/s12975-012-0215-4. [DOI] [PubMed] [Google Scholar]
  • 171.Belayev L, Liu Y, Zhao W, Busto R, Ginsberg M D. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke. 2001;32(2):553–560. doi: 10.1161/01.str.32.2.553. [DOI] [PubMed] [Google Scholar]
  • 172.Ginsberg M D, Hill M D, Palesch Y Y, Ryckborst K J, Tamariz D. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--I Physiological responses and safety results. Stroke. 2006;37(8):2100–2106. doi: 10.1161/01.STR.0000231388.72646.05. [DOI] [PubMed] [Google Scholar]
  • 173.Chen J, Fredrickson V, Ding Y, Cheng H, Wang N, Ling F, Ji X. Enhanced neuroprotection by local intra-arterial infusion of human albumin solution and local hypothermia. Stroke. 2013;44(1):260–262. doi: 10.1161/STROKEAHA.112.675462. [DOI] [PubMed] [Google Scholar]
  • 174.Ivamoto H S, Numoto M, Donaghy R M. Surgical decompression for cerebral and cerebellar infarcts. Stroke. 1974;5(3):365–370. doi: 10.1161/01.str.5.3.365. [DOI] [PubMed] [Google Scholar]
  • 175.Doerfler A, Schwab S, Hoffmann T T, Engelhorn T, Forsting M. Combination of decompressive craniectomy and mild hypothermia ameliorates infarction volume after permanent focal ischemia in rats. Stroke. 2001;32(11):2675–2681. doi: 10.1161/hs1101.098369. [DOI] [PubMed] [Google Scholar]
  • 176.Jieyong B, Zhong W, Shiming Z, Dai Z, Kato Y, Kanno T, Sano H. Decompressive craniectomy and mild hypothermia reduces infarction size and counterregulates Bax and Bcl-2 expression after permanent focal ischemia in rats. Neurosurg. Rev. 2006;29(2):168–172. doi: 10.1007/s10143-005-0010-8. [DOI] [PubMed] [Google Scholar]
  • 177.Els T, Oehm E, Voigt S, Klisch J, Hetzel A, Kassubek J. Safety and therapeutical benefit of hemicraniectomy combined with mild hypothermia in comparison with hemicraniectomy alone in patients with malignant ischemic stroke. Cerebrovasc. Dis. 2006;21(1-2):79–85. doi: 10.1159/000090007. [DOI] [PubMed] [Google Scholar]
  • 178.Lawrence M S, McLaughlin J R, Sun G H, Ho D Y, McIntosh L, Kunis D M, Sapolsky R M, Steinberg G K. Herpes simplex viral vectors expressing Bcl-2 are neuroprotective when delivered after a stroke. J. Cereb. Blood Flow Metab. 1997;17(7):740–744. doi: 10.1097/00004647-199707000-00003. [DOI] [PubMed] [Google Scholar]
  • 179.Zhao H, Yenari M A, Sapolsky R M, Steinberg G K. Mild postischemic hypothermia prolongs the time window for gene therapy by inhibiting cytochrome C release. Stroke. 2004;35(2):572–577. doi: 10.1161/01.STR.0000110787.42083.58. [DOI] [PubMed] [Google Scholar]
  • 180.Wadia J S, Dowdy S F. Protein transduction technology. Curr. Opin. Biotechnol. 2002;13(1):52–56. doi: 10.1016/s0958-1669(02)00284-7. [DOI] [PubMed] [Google Scholar]
  • 181.Beerens A M, Al Hadithy A F, Rots M G, Haisma H J. Protein transduction domains and their utility in gene therapy. Curr. Gene Ther. 2003;3(5):486–494. doi: 10.2174/1566523034578258. [DOI] [PubMed] [Google Scholar]
  • 182.Denicourt C, Dowdy S F. Protein transduction technology offers novel therapeutic approach for brain ischemia. Trends Pharmacol. Sci. 2003;24(5):216–218. doi: 10.1016/S0165-6147(03)00074-9. [DOI] [PubMed] [Google Scholar]
  • 183.Asoh S, Ohsawa I, Mori T, Katsura K, Hiraide T, Katayama Y, Kimura M, Ozaki D, Yamagata K, Ohta S. Protection against ischemic brain injury by protein therapeutics. Proc. Natl. Acad. Sci. U.S.A. 2002;99(26):17107–17112. doi: 10.1073/pnas.262460299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 184.Katsura K, Takahashi K, Asoh S, Watanabe M, Sakurazawa M, Ohsawa I, Mori T, Igarashi H, Ohkubo S, Katayama Y, Ohta S. Combination therapy with transductive anti-death FNK protein and FK506 ameliorates brain damage with focal transient ischemia in rat. J. Neurochem. 2008;106(1):258–270. doi: 10.1111/j.0022-3042.2008.05360.x. [DOI] [PubMed] [Google Scholar]
  • 185.Sakurazawa M, Katsura K, Saito M, Asoh S, Ohta S, Katayama Y. Mild hypothermia enhanced the protective effect of protein therapy with transductive anti-death FNK protein using a rat focal transient cerebral ischemia model. Brain. Res. 2012;1430:86–92. doi: 10.1016/j.brainres.2011.10.041. [DOI] [PubMed] [Google Scholar]
  • 186.Vannucci R C, Perlman J M. Interventions for perinatal HI-ischemic encephalopathy. Pediatrics. 1997;100(6):1004–1014. doi: 10.1542/peds.100.6.1004. [DOI] [PubMed] [Google Scholar]
  • 187.Levene M I, Sands C, Grindulis H, Moore J R. Comparison of two methods of predicting outcome in perinatal asphyxia. Lancet. 1986;1(8472):67–69. doi: 10.1016/s0140-6736(86)90718-x. [DOI] [PubMed] [Google Scholar]
  • 188.Hobbs C, Thoresen M, Tucker A, Aquilina K, Chakkarapani E, Dingley J. Xenon and hypothermia combine additively, offering long-term functional and histopathologic neuroprotection after neonatal hypoxia/ischemia. Stroke. 2008;39(4):1307–1313. doi: 10.1161/STROKEAHA.107.499822. [DOI] [PubMed] [Google Scholar]
  • 189.Ikonomidou C, Mosinger J L, Olney J W. Hypothermia enhances protective effect of MK-801 against hypoxic/ischemic brain damage in infant rats. Brain Res. 1989;487(1):184–187. doi: 10.1016/0006-8993(89)90956-6. [DOI] [PubMed] [Google Scholar]
  • 190.Alkan T, Kahveci N, Buyukuysal L, Korfali E, Ozluk K. Neuroprotective effects of MK 801 and hypothermia used alone and in combination in hypoxic-ischemic brain injury in neonatal rats. Arch Physiol Biochem. 2001;109(2):135–144. doi: 10.1076/apab.109.2.135.4271. [DOI] [PubMed] [Google Scholar]
  • 191.Xu S Y, Pan S Y. The failure of animal models of neuroprotection in acute ischemic stroke to translate to clinical efficacy. Med. Sci. Monit. Basic Res. 2013;19:37–45. doi: 10.12659/MSMBR.883750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 192.Fisher M, Albers G W, Donnan G A, Furlan A J, Grotta J C, Kidwell C S, Sacco R L, Wechsler L R. Stroke Therapy Academic Industry Roundtable, I.V. Enhancing the development and approval of acute stroke therapies Stroke Therapy Academic Industry roundtable. . Stroke. 2005;36(8):1808–1813. doi: 10.1161/01.STR.0000173403.60553.27. [DOI] [PubMed] [Google Scholar]

Articles from Current Neuropharmacology are provided here courtesy of Bentham Science Publishers

RESOURCES